Uptake and hesitancy of the second booster dose of COVID-19 vaccine among the general population in China after the surge period of the COVID-19 pandemic: a large-scale national st... by Xin Liu, You Xin, Ling Zhang, Yijin Wu, Shu Jing, Zhenwei Dai, Tianrui Ren, Xiaoyang Liu, Jiaqi Fu, Xu Chen, Weijun Xiao, Hao Wang, Yiman Huang, Wenjun Wang, Xiaofen Gu, Li Ma, Shaokai Zhang, Yanqin Yu, Li Li, Tianzuo Gao, Tianyou Zhao, Yimin Qu, Xinyan Liu, Xiaoyou Su, Youlin Qiao

“…Abstract Background Although the second booster dose of COVID-19 vaccines is available, vaccine hesitancy among the public may have peaked due to the surge in infections caused by the Omicron variant. To improve coverage of the second booster dose, it is crucial to investigate the prevalence of vaccine hesitancy among the general population during this period and explore the reasons for this phenomenon. …”
Get full text

Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescentsResearch in context by Qiong Wu, Bingyu Zhang, Jiayi Tong, L. Charles Bailey, H. Timothy Bunnell, Jiajie Chen, Elizabeth A. Chrischilles, Dimitri A. Christakis, Stephen M. Downs, Kathryn Hirabayashi, Aaron D. Mishkin, Abu S.M. Mosa, Nathan M. Pajor, Suchitra Rao, Hanieh Razzaghi, Hayden T. Schwenk, Marion R. Sills, Huiyuan Wang, Linbo Wang, Yudong Wang, Dazheng Zhang, Ting Zhou, Ravi Jhaveri, Eric J. Tchetgen Tchetgen, Jeffrey S. Morris, Christopher B. Forrest, Yong Chen

“…Findings: 112,590 adolescents (88,811 vaccinated) were included in the cohort for the analysis against Delta variant, and 188,894 children (101,277 vaccinated), and 84,735 adolescents (37,724 vaccinated) were included for the analysis against Omicron variant. During the Delta period, the estimated effectiveness of the BNT162b2 vaccine against long COVID among adolescents was 95.4% (95% CI: 90.9%–97.7%). …”
Get full text

Nanobody screening and machine learning guided identification of cross-variant anti-SARS-CoV-2 neutralizing heavy-chain only antibodies. by Peter R McIlroy, Le Thanh Mai Pham, Thomas Sheffield, Maxwell A Stefan, Christine E Thatcher, James Jaryenneh, Jennifer L Schwedler, Anupama Sinha, Christopher A Sumner, Iris K A Jones, Stephen Won, Ryan C Bruneau, Dina R Weilhammer, Zhuoming Liu, Sean Whelan, Oscar A Negrete, Kenneth L Sale, Brooke Harmon

“…Using HCAb affinity for SARS-CoV-2 VOI and VOCs (pre-Omicron variants) and model features from other published data, we were able to develop a ML model that successfully identified HCAbs with efficacy against Omicron variants, independent of our experimental biopanning workflow. …”
Get full text

A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5 by Zhe Chen, Leilei Feng, Lei Wang, Li Zhang, Binyang Zheng, Hua Fu, Fengdi Li, Ligai Liu, Qi Lv, Ran Deng, YanLi Xu, Yongfeng Hu, Jianhua Zheng, Chuan Qin, Linlin Bao, Xiangxi Wang, Qi Jin

“…This evasion highlights the urgency in discovering new monoclonal antibodies (mAbs) with neutralizing activity, especially broadly neutralizing antibodies (bnAbs), to combat the virus.In the current study, we introduced a fully human neutralizing mAb, CR9, that targets Omicron variants. We demonstrated the mAb’s effectiveness in inhibiting Omicron replication both in vitro and in vivo. …”
Get full text

Fc-binding nanodisc restores antiviral efficacy of antibodies with reduced neutralizing effects against evolving SARS-CoV-2 variants by Jaehyeon Hwang, Soyun Choi, Beom Kyu Kim, Sumin Son, Jeong Hyeon Yoon, Kyung Won Kim, Wonbeom Park, Hyunjoo Choo, Suhyun Kim, Soomin Kim, Seokhyeon Yu, Sangwon Jung, Sang Taek Jung, Min-Suk Song, Sang Jick Kim, Dae-Hyuk Kweon

“…Notably, Sotrovimab, an FDA-approved monoclonal antibody that has experienced a significant decline in neutralizing potency due to viral evolution, exhibited robust antiviral activity when complexed with the nanodisc against all tested Omicron variants. Furthermore, the Fc-binding nanodisc significantly boosted the antiviral efficacy of the soluble angiotensin-converting enzyme 2 (sACE2) Fc fusion protein, which possesses broad but modest antiviral activity. …”
Get full text

Characterization of Vaccine-Enhanced Humoral Immune Responses Against Emergent SARS-CoV-2 Variants in a Convalescent Cohort by Jared Sheehan, Amber J. Trauth, Michael E. Hagensee, Alistair J. Ramsay

“…However, sera collected from vaccinated convalescent subjects also had significant neutralization activity against Delta B.1.617.2 and Omicron variants that persisted for at least 2–3 months, unlike sera from unvaccinated convalescent controls. …”
Get full text

mRNA vaccines with RBD mutations have broad-spectrum activity against SARS-CoV-2 variants in mice by Xiaoming Liang, Yuxia Yuan, Junbin Wang, Cong Tang, Yun Yang, Yanan Zhou, Hao Yang, Qing Huang, Wenhai Yu, Haixuan Wang, Yuhuan Yan, Dongdong Lin, Yanwen Li, Xuena Du, Longhai Yuan, Wenqi Quan, Daoju Wu, Shuaiyao Lu

“…Moreover, all three vaccines induced neutralizing antibodies against the prototype viral strain and relevant variants, including the Alpha and Beta strains and the Omicron variants BA.1, BA.2, BA.5, XBB.1.5, XBB.1.16, EG.5.1, and EG.5.1.1, with BSCoV06 demonstrating broader neutralizing antibody activity. …”
Get full text

Safety and Intranasal Retention of a Broad-Spectrum Anti-SARS-CoV-2 Monoclonal Antibody SA55 Nasal Spray in Healthy Volunteers: A Phase I Clinical Trial by Chaoying Hu, Yibo Zhou, Xing Meng, Jianhua Li, Jinxia Chen, Zhifang Ying, Xiaoliang Sunney Xie, Yaling Hu, Yunlong Cao, Ronghua Jin

“…Conclusions: This study demonstrated favorable safety and tolerability of the SA55 nasal spray in healthy volunteers, exhibited satisfactory neutralizing activity against Omicron variants intranasally, and indicated low systemic toxicity risk.…”
Get full text

Evaluation of IgG binding capability to SARS-CoV-2 variants in early COVID-19 convalescent sera using an indirect ELISA by Behzad Hussain, Peizhe Zhao, Yu Liu, Bo Yang, Xiaoxiong Li, Zhichao Zhang, Guoqiang Feng, Demei Zhang, Defen Lu, Wu Changxin

“…Hence, in this study, RBD of Alpha, Beta, Gamma, Kappa and Omicron BA.1 and full-length spike of BA.1, BA.2, BA.3, BA.4/5, BQ.1.1 and XBB.1.5 Omicron variants were used as coating antigens in an indirect Enzyme Linked Immuno-Sorbent Assay (ELISA) to check the IgG binding capability to the COVID-19 convalescent sera from patients of first wave of infection occurring in Wuhan. …”
Get full text

The Long-Term Immunity of a Microneedle Array Patch of a SARS-CoV-2 S1 Protein Subunit Vaccine Irradiated by Gamma Rays in Mice by Eun Kim, Muhammad S. Khan, Juyeop Shin, Shaohua Huang, Alessandro Ferrari, Donghoon Han, Eunjin An, Thomas W. Kenniston, Irene Cassaniti, Fausto Baldanti, Dohyeon Jeong, Andrea Gambotto

“…The immune responses of the MAP with and without gamma irradiation as terminal sterilization were assessed at doses of 5, 15, and 45 µg, alongside neutralizing antibody responses to Wuhan, Delta, and Omicron variants. The long-term storage stability was also evaluated through protein degradation analyses at varying temperatures. …”
Get full text

Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages by Jingyun Yang, Xuemei He, Huashan Shi, Cai He, Hong Lei, Heng He, Li Yang, Wei Wang, Guobo Shen, Jinliang Yang, Zhiwei Zhao, Xiangrong Song, Zhenling Wang, Guangwen Lu, Jiong Li, Yuquan Wei

“…We further investigated humoral immune response of recombinant XBB vaccines against Omicron variants and estimated the neutralization resistance of JN.1 sublineages, including KP.2 and KP.3. …”
Get full text